Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 11/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232867 | 0.88 | MAPT (0.42) | LTC4SL3MBTL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2743209 | 0.86 | LMNA (0.46) | LTC4SSRD5A2CTRCL3MBTL1LMNA | |
| SCHEMBL233590 | 0.85 | SRD5A2 (0.42) | LTC4SSRD5A2CTRCL3MBTL1LMNA | |
| SCHEMBL233511 | 0.84 | LMNA (0.47) | LTC4SSRD5A2L3MBTL1LMNAMAPT | |
| SCHEMBL9988366 | 0.83 | LTC4S (0.50) | LTC4SRHEB | |
| SCHEMBL2743210 | 0.82 | LTC4S (0.41) | LTC4SSRD5A2CTRCL3MBTL1LMNA | |
| SCHEMBL232053 | 0.81 | LTC4S (0.47) | LTC4SL3MBTL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL232237 | 0.80 | SRD5A2 (0.56) | LTC4SSRD5A2L3MBTL1LMNAMAPT | |
| SCHEMBL230420 | 0.80 | LTC4S (0.43) | LTC4SSRD5A2L3MBTL1LMNAMAPT | |
| SCHEMBL232069 | 0.80 | LTC4S (0.53) | LTC4SRHEBL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2011-12-29 | — | — | US | disclosed |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2011-12-29 | — | — | US | disclosed |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | LTC4S 1/4885SRD5A2 1138/4885RHEB 3377/4885 |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | LTC4S 1/4885SRD5A2 564/4885RHEB 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.